Peter Makram Salama is a biotechnology leader with over a decade of experience in process development, R&D, and biopharmaceutical manufacturing. As R&D Manager for mRNA and Vaccines at EVA Pharma, he leads the company’s new biologics division and oversees its mRNA technology platform, managing the full development lifecycle from basic research to commercial production while driving global collaborations and contributing to the design of EVA Pharma’s new biomanufacturing facility. Previously, as Head of Upstream at Minapharm Pharmaceuticals, he led the technology transfer and scale‑up of a COVID‑19 vaccine and developed robust upstream processes for major monoclonal antibody biosimilars. He holds a Bachelor’s degree in Pharmaceutical Sciences from Ain Shams University and brings deep expertise in mammalian and yeast expression systems, supported by strong strategic and leadership capabilities.

Peter Salama was elected to the AVMI board at the AVMI AGM in 2026.